Ali Behbahani, M.D. takes on role of Chairperson of the Board
See the article here:
Oyster Point Pharma Announces Board of Directors Leadership Changes and New Appointment as the Company Advances into Next Phase of Growth
Third Quarter 2020 Revenue Expected to Represent Approximately 104% Year-Over-Year Growth Third Quarter 2020 Revenue Expected to Represent Approximately 104% Year-Over-Year Growth
Read this article:
GenMark Diagnostics Provides Preliminary Financial Results for Third Quarter 2020
Application of ImmTOR™ plus IGAN’s IgA protease to target immunoglobulin A (IgA) deposition, the critical event leading to IgA Nephropathy (IgAN)
Go here to see the original:
Selecta Biosciences and IGAN Biosciences Enter into Research License and Option Agreement to Study Selecta’s ImmTOR™ Immune Tolerance Platform in...
Combination test for COVID-19, flu and other common respiratory illnesses helps health care professionals prepare for flu season Combination test for COVID-19, flu and other common respiratory illnesses helps health care professionals prepare for flu season
Read more:
GenMark Diagnostics’ ePlex® Respiratory Pathogen Panel 2 (RP2) Receives EUA from FDA
VALENCIA, Calif., Oct. 06, 2020 (GLOBE NEWSWIRE) -- SetPoint Medical, Inc. today announced that it has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for the use of its novel bioelectronic device for patients with rheumatoid arthritis (RA) who have incomplete response to, or are intolerant to multiple biologic drugs. The Company is developing its platform for the treatment of chronic, inflammation-mediated autoimmune diseases, and is initially focused on the treatment of RA as a potentially efficacious, yet less immunosuppressive option.
Read the original here:
SetPoint Medical Receives FDA Breakthrough Device Designation for its Novel Bioelectronic Platform
Oslo, 06 October 2020
Here is the original post:
PCI Biotech: Employee share option scheme
VANCOUVER, British Columbia, Oct. 06, 2020 (GLOBE NEWSWIRE) -- Derm-Biome Pharmaceuticals, Inc, a private Vancouver based biopharmaceutical company focused on skin health and healthy ageing, is pleased to announce that one of its topical drugs produced significant, and dose dependent inhibitory effects in a well established mouse model of psoriasis. Psoriasis is a chronic inflammatory skin disease often linked to depression and a decreased quality of life. The global psoriasis treatment market is projected to reach USD $37 billion by 2026. These results come on the heels of a successful preclinical study in atopic dermatitis earlier this year using the same drug.
Read more from the original source:
Derm-Biome Pharmaceuticals, Inc. Reports Positive Results from a Preclinical Study In Psoriasis
Ljubljana, Slovenia, Oct. 06, 2020 (GLOBE NEWSWIRE) -- Rafarma Pharmaceuticals, Inc. OTC:(RAFA) is pleased to announce approval of Ilya Shpurov receiving the majority of Preferred B shares, conferring voting control of the company, toward the combination of its acquisition by R. & D. BIOCOGENCY LABORATORIES Group of Companies. The issuance of restricted preferred shares does not create any dilution of common shares.
See the original post here:
Rafarma Approves Issuance of Majority of Voting Shares to Board Chairman Ilya Shpurov
·BYFAVO expected to be commercially available in the US before the end of the year This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014.
See the article here:
Acacia Pharma announces BYFAVO™ (remimazolam), its Newly Approved Product for Procedural Sedation, Clears Final Hurdle on Path to Commercial Launch...